DeepMed Research

The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Phase 2

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Monocytic Leukemia (M5b)

Interventions: Drug: eltrombopag olamine

First Posted Date: 2014-02-26

Last Posted Date: 2021-12-01

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 31

Registration Number: NCT02071901

Locations: 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Refractory Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: ixazomib
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine

First Posted Date: 2014-02-25

Last Posted Date: 2018-12-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT02070458

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer

Phase 2

Withdrawn

Conditions: Stage II Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer
Stage I Adult Primary Liver Cancer
Stage IIIA Adult Primary Liver Cancer
Adult Primary Hepatocellular Carcinoma

Interventions: Procedure: transarterial chemoembolization
Radiation: stereotactic radiosurgery

First Posted Date: 2014-02-25

Last Posted Date: 2014-12-02

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT02070419

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Disease
Sickle Cell Anemia
SCD

Interventions: Drug: Fludarabine
Procedure: Hematopoietic Stem Cell Transplant (HSCT)

First Posted Date: 2014-02-19

Last Posted Date: 2024-04-29

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT02065596

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Other: fluorine F 18 fluorothymidine
Device: positron emission tomography
Device: magnetic resonance imaging

First Posted Date: 2014-02-05

Last Posted Date: 2020-09-18

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT02055586

Locations: 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Stage IIIC Esophageal Cancer
Adenocarcinoma of the Gastric Cardia
Stage IIIA Esophageal Cancer
Stage IIIB Esophageal Cancer

Interventions: Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2014-01-15

Last Posted Date: 2024-01-08

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 63

Registration Number: NCT02037048

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

Not Applicable

Terminated

Conditions: Adenocarcinoma of the Prostate Stage III
Adenocarcinoma of Prostate
Adenocarcinoma of the Prostate Stage I
Adenocarcinoma of the Prostate Stage II

Interventions: Behavioral: Personalized Treatment Recommendations
Behavioral: Standard patient-physician counseling interaction

First Posted Date: 2013-12-31

Last Posted Date: 2015-11-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 76

Registration Number: NCT02024685

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Improving Erectile Function and Quality of Life After Prostate Cancer Treatment

Not Applicable

Terminated

Conditions: Prostate Cancer
Erectile Dysfunction Following Radical Prostatectomy
Erectile Dysfunction
Erectile Dysfunction Following Simple Prostatectomy

Interventions: Behavioral: Cognitive-behavioral Meetings
Drug: sildenafil citrate
Device: Vacuum Constriction Device

First Posted Date: 2013-11-27

Last Posted Date: 2019-05-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 34

Registration Number: NCT01996852

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Primary Central Nervous System Non-Hodgkin Lymphoma

Interventions: Biological: rituximab
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2013-10-31

Last Posted Date: 2020-07-24

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT01973062

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

Phase 2

Completed

Conditions: Stage II Breast Cancer
Stage IIIC Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer

Interventions: Biological: trastuzumab
Drug: doxorubicin
Biological: Pertuzumab
Drug: cyclophosphamide
Drug: docetaxel
Drug: paclitaxel
Drug: Bevacizumab
Drug: carboplatin

First Posted Date: 2013-10-10

Last Posted Date: 2019-03-05

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT01959490

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy